Study Finds Letrozole May Increase Risk of Osteoporosis in Postmenopausal Women

Letrozole is a medication that belongs to a class of drugs known as aromatase inhibitors. It is commonly used to treat hormone receptor-positive breast cancer in postmenopausal women. Letrozole works by decreasing the amount of estrogen produced in the body, which helps slow down or stop the growth of cancer cells.

One of the main uses of letrozole is in the adjuvant treatment of early-stage breast cancer in women who have already undergone surgery to remove the tumor. It is also used in the treatment of advanced or metastatic breast cancer that has spread to other parts of the body. Letrozole may be prescribed alone or in combination with other medications.

Letrozole is usually taken orally in the form of a tablet once a day, with or without food. It is important to follow the dosing schedule provided by your healthcare provider and not to miss any doses. Common side effects of letrozole may include hot flashes, fatigue, joint pain, and bone thinning.

Study Finds Letrozole May Increase Risk of Osteoporosis in Postmenopausal Women

It is important to discuss any potential benefits and risks of letrozole treatment with your doctor before starting this medication. Your healthcare provider will monitor your response to letrozole and may adjust your dosage or switch to a different treatment if necessary. Overall, letrozole is an important drug in the management of breast cancer and has been shown to be effective in reducing the risk of cancer recurrence.

Discover the benefits of letrozole, a potent aromatase inhibitor commonly used in hormone therapy and bodybuilding. Explore more at:


In conclusion, letrozole has been shown to have a variety of effects that can impact individuals using this medication. It is important for patients to discuss any potential side effects with their healthcare provider and monitor their symptoms closely while taking letrozole.

Leave a Comment

Your email address will not be published. Required fields are marked *